Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Groundbreaking twice-yearly jab could transform lives of high cholesterol sufferers by replacing daily statin tablets

Injection would be ‘game-changer’ for millions, doctors say

Chiara Giordano
Monday 02 September 2019 20:39 EDT
Comments
File image.
File image. (iStock/Getty)

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

A twice-yearly jab which replaces daily statins could be a “game changer” for millions of people with high cholesterol, scientists say.

A landmark study of 1,600 people over 18 months found that the injection halved the levels of “bad” cholesterol in the blood without any apparent side effects.

Doctors say the drug, called Inclisiran, showed “phenomenal” results and could transform the lives of millions of people who have to take statin tablets every day.

It could also help lower the risk of a heart attack or stroke, they say.

Kausik Ray, professor of public health and consultant cardiologist at Imperial College London, led the study for the Medicines Company, which is developing the drug.

Presenting the findings to leading cardiologists at the European Society of Cardiology Congress in Paris, he said: “It’s a game changer to manage cholesterol. The convenience is key.”

It is hoped the jab could be on the market within about two years.

Researchers hope it will improve the lives of people living with high cholesterol who forget to take their statins or suffer side effects from the pills.

Support free-thinking journalism and attend Independent events

Prof Ray said it would initially be taken alongside daily statin tablets and could help up to about 700,000 people in the UK.

Mark Timney, chief executive of The Medicines Company, said: “We are excited at the prospect of bringing forward a remarkable, transformative advance in the treatment of cardiovascular disease.”

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in